Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 1/20 | 0.31 |
| ▸ | CCND1 | P24385 | 1/20 | 0.31 |
| ▸ | CCND3 | P30281 | 1/20 | 0.31 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.30 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3100228 | 1.00 | CDK4 (0.31) | CDK4CCND1CCND3CDK6KCNH2 | |
| SCHEMBL3104542 | 0.89 | KCNH2 (0.34) | KCNH2SLC2A1CHRM4 | |
| SCHEMBL3104536 | 0.89 | KCNH2 (0.34) | KCNH2SLC2A1CHRM4 | |
| SCHEMBL3106752 | 0.87 | OPRM1 (0.35) | KCNH2SLC2A1 | |
| SCHEMBL3982714 | 0.82 | PTPN11 (0.35) | KCNH2SLC2A1 | |
| SCHEMBL3100022 | 0.82 | PTPN11 (0.35) | KCNH2SLC2A1 | |
| SCHEMBL3328907 | 0.79 | KCNH2 (0.39) | CDK4CCND1CCND3CDK6KCNH2 | |
| SCHEMBL3102152 | 0.77 | DRD4 (0.33) | KCNH2 | |
| SCHEMBL3984347 | 0.76 | KCNH2 (0.39) | KCNH2SLC2A1 | |
| SCHEMBL3090361 | 0.76 | SSTR4 (0.40) | KCNH2SLC2A1CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100256124-A1 | Substituted 1-Methyl-1H-Quinolin-2-Ones And 1-Methyl-1H-1,5-Naphthyridin-2-Ones As Antibacterials | GLAXO GROUP LIMITED (GB) | 2010-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256124-A1 | Substituted 1-Methyl-1H-Quinolin-2-Ones And 1-Methyl-1H-1,5-Naphthyridin-2-Ones As Antibacterials | TOP1, TOP2A, NDC1 | CDK4 1446/4885CCND1 1479/4885CCND3 1535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.